

Pending Claims

1. (Previously presented) A pharmaceutical composition comprising:
a first therapeutic agent selected from the group consisting of:
 azo-bonded 4-APAA compound;
 non-azo bonded 4-APAA compound;
 azo-bonded 5-ASA compound;
 non-azo bonded 5-ASA compound; and
a second therapeutic agent comprising a
 4-APAA compound azo bonded to a 5-ASA compound.
2. (Previously presented) The pharmaceutical composition of claim 1 further comprising another therapeutic agent selected from the group consisting of: steroids, antibiotics, stool softeners, stool hardeners, nutraceuticals, probiotic agents and organisms, and nicotinic agents.
3. (Previously presented) The pharmaceutical composition of claim 1 formulated to deliver the first therapeutic agent to the small intestine.
4. (Previously presented) The pharmaceutical composition of claim 1 formulated to release the first therapeutic agents along the length of the small intestine and the second therapeutic agent along the length of colon.
5. (Previously presented) The pharmaceutical composition of claim 1 formulated to release the second therapeutic agents along the length of the distal portion of the small intestine and the colon.
6. (Previously presented) The pharmaceutical composition of claim 1 formulated to release the second therapeutic agents along the length of the colon.
7. (Original) The pharmaceutical composition of claim 1 formulated to pass through the stomach and to release the active agent in the intestine.
8. (Previously presented) The pharmaceutical composition of claim 1 formulated as a suppository.

9. (Previously presented) The pharmaceutical composition of claim 1 formulated for administration as an enema.

10-14. (Cancelled)

15. (Previously presented) A pharmaceutical composition comprising at least

a first and second therapeutic agent, wherein the first therapeutic agent is formulated to release in the stomach or small intestine and selected from the group consisting of

azo-bonded 4-APAA compound;

non-azo bonded 4-APAA compound;

azo-bonded 5-ASA compound; and

non-azo bonded 5-ASA compound; and

wherein the second therapeutic agent is formulated to release in the distal portion of the small intestine or colon and selected from the group consisting of:

4-APAA compound azo bonded to a 5-ASA compound; and

a combination of 4-APAA compound and a 5-ASA compound.

16.-29. (Cancelled)

30. (Previously presented) A method of treating an inflammatory colon condition comprising administering to a subject a pharmaceutical composition of claim 1 or 15 in an amount sufficient to reduce the inflammatory inflammatory colon condition.

31.-32. (Cancelled).

33. (Previously presented) The pharmaceutical composition of claim 15 wherein:

the first therapeutic agent is a 5-ASA compound formulated for release in the stomach and the second therapeutic agent is a 4-APAA compound azo bonded to a 5-ASA compound formulated for release in a distal portion of the small intestine.

34. -38. Cancelled

39. (Previously presented) The pharmaceutical composition of claim 15 wherein:
the first therapeutic agent is a 5-ASA compound formulated for release in the small intestine and the
second therapeutic agent is a 4-APAA compound azo bonded to a 5-ASA compound formulated for
release in the colon.

40. (Cancelled)